医药板块今日集体上行，恒生创新药ETF（159316）全天获2100万份净申购

Group 1 - The pharmaceutical sector experienced a collective rise, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increasing by 1.4% and the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 0.9% [1] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 21 million units throughout the day, with approximately 500 million yuan raised last week, bringing its total size to nearly 3.3 billion yuan, a record high [1] - Tianfeng Securities indicated that China's innovative drug industry has formed a pyramid structure led by top enterprises, supported by a large number of quality companies, with strong sustainability in the industry [1] Group 2 - The index focuses on leading innovative drug companies in A-shares, consisting of no more than 50 stocks involved in innovative drug research and development [4] - The rolling price-to-earnings ratio of the index is 54.0 times, with a 0.5% increase since its release [5] - The biotechnology ETF tracks the China Securities Biotechnology Theme Index, which focuses on leading biotechnology companies in A-shares, comprising no more than 50 stocks involved in gene diagnosis, biopharmaceuticals, and other human biotechnology [6] Group 3 - The index for the biotechnology sector has a rolling price-to-earnings ratio of 59.6 times, with a 0.5% increase since its release [7] - The healthcare ETF tracks the CSI 300 Pharmaceutical and Health Index, focusing on leading companies in the pharmaceutical and health industry within the CSI 300 Index, covering various segments of the future health industry [8] - The rolling price-to-earnings ratio for the healthcare index is 31.6 times, with a 0.2% increase since its release [9]